FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362656989> ?p ?o ?g. }

• W4362656989 endingPage "459" @default.
• W4362656989 startingPage "459" @default.
• W4362656989 abstract "Dry eye disease (DED) is a common public health problem with significant impact on vision-related quality of life and well-being of patients. Medications with rapid onset of action and a good tolerability profile remain an unmet need.To assess efficacy, safety, and tolerability of a water-free cyclosporine ophthalmic solution, 0.1% (CyclASol [Novaliq GmbH]), applied twice daily in DED compared with vehicle.CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (ESSENCE-2) was a phase 3, multicenter, randomized, double-masked, vehicle-controlled clinical study conducted from December 5, 2020, to October 8, 2021. Following a 14-day run-in period with an artificial tear administered 2 times per day, eligible participants were randomly assigned 1:1 to the treatment groups. Patients with moderate to severe DED were included in the study.Cyclosporine solution vs vehicle administered 2 times per day for 29 days.The primary end points were changes from baseline in total corneal fluorescein staining (tCFS; 0-15 National Eye Institute scale) and in dryness score (0-100 visual analog scale) at day 29. Conjunctival staining, central corneal fluorescein staining, and tCFS responders were also assessed.A total of 834 study participants were randomly assigned to cyclosporine (423 [50.7%]) or vehicle (411 [49.3%]) groups at 27 sites. Participants had a mean (SD) age of 57.1 (15.8) years, and 609 (73.0%) were female individuals. The majority of participants self-identified in the following race categories: 79 Asian (9.5 %), 108 Black (12.9%), and 635 White (76.1%). Participants treated with cyclosporine solution had greater improvement in tCFS (-4.0 grades) than the vehicle group (-3.6 grades) at day 29 (change [∆] = -0.4; 95% CI, -0.8 to 0; P = .03). The dryness score showed treatment benefits from baseline in both groups: -12.2 points for cyclosporine and -13.6 points for vehicle (∆ = 1.4; 95% CI, -1.8 to 4.6; P = .38). In the cyclosporine group, 293 participants (71.6%) achieved clinically meaningful reductions of 3 grades or higher in tCFS vs 236 (59.7%) in the vehicle group (∆ = 12.6%; 95% CI, 6.0%-19.3%; P < .001). These responders showed greater improvement in symptoms at day 29 including dryness (∆ = -4.6; 95% CI, -8.0 to -1.2; P = .007) and blurred vision (Δ = -3.5; 95% CI, -6.6 to -4.0; P = .03) compared with nonresponders.The ESSENCE-2 trial confirmed that treatment with a water-free cyclosporine solution, 0.1%, results in early therapeutic effects on the ocular surface compared with vehicle. The responder analyses suggest that the effect is clinically meaningful in 71.6% of participants in the cyclosporine group.ClinicalTrials.gov Identifier: NCT04523129." @default.
• W4362656989 created "2023-04-07" @default.
• W4362656989 creator A5010870123 @default.
• W4362656989 creator A5012925663 @default.
• W4362656989 creator A5025291618 @default.
• W4362656989 creator A5035436551 @default.
• W4362656989 creator A5038581698 @default.
• W4362656989 creator A5066770174 @default.
• W4362656989 creator A5078689711 @default.
• W4362656989 creator A5087676704 @default.
• W4362656989 date "2023-05-01" @default.
• W4362656989 modified "2023-10-01" @default.
• W4362656989 title "Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease" @default.
• W4362656989 cites W1523354060 @default.
• W4362656989 cites W1996397549 @default.
• W4362656989 cites W2019761152 @default.
• W4362656989 cites W2068584868 @default.
• W4362656989 cites W2093545788 @default.
• W4362656989 cites W2118607752 @default.
• W4362656989 cites W2318533725 @default.
• W4362656989 cites W2512928733 @default.
• W4362656989 cites W2574040535 @default.
• W4362656989 cites W2735923669 @default.
• W4362656989 cites W2736163580 @default.
• W4362656989 cites W2737439597 @default.
• W4362656989 cites W2739359388 @default.
• W4362656989 cites W2739410682 @default.
• W4362656989 cites W2784031181 @default.
• W4362656989 cites W2799529947 @default.
• W4362656989 cites W2808085391 @default.
• W4362656989 cites W2895808676 @default.
• W4362656989 cites W2914403907 @default.
• W4362656989 cites W2930314817 @default.
• W4362656989 cites W2940458991 @default.
• W4362656989 cites W2990862495 @default.
• W4362656989 cites W3122362139 @default.
• W4362656989 cites W3128823428 @default.
• W4362656989 cites W3163100709 @default.
• W4362656989 cites W3202889207 @default.
• W4362656989 cites W3209166603 @default.
• W4362656989 cites W4210503992 @default.
• W4362656989 cites W4281388915 @default.
• W4362656989 cites W4285698150 @default.
• W4362656989 cites W4312203732 @default.
• W4362656989 doi "https://doi.org/10.1001/jamaophthalmol.2023.0709" @default.
• W4362656989 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37022717" @default.
• W4362656989 hasPublicationYear "2023" @default.
• W4362656989 type Work @default.
• W4362656989 citedByCount "4" @default.
• W4362656989 countsByYear W43626569892023 @default.
• W4362656989 crossrefType "journal-article" @default.
• W4362656989 hasAuthorship W4362656989A5010870123 @default.
• W4362656989 hasAuthorship W4362656989A5012925663 @default.
• W4362656989 hasAuthorship W4362656989A5025291618 @default.
• W4362656989 hasAuthorship W4362656989A5035436551 @default.
• W4362656989 hasAuthorship W4362656989A5038581698 @default.
• W4362656989 hasAuthorship W4362656989A5066770174 @default.
• W4362656989 hasAuthorship W4362656989A5078689711 @default.
• W4362656989 hasAuthorship W4362656989A5087676704 @default.
• W4362656989 hasBestOaLocation W43626569891 @default.
• W4362656989 hasConcept C118487528 @default.
• W4362656989 hasConcept C126322002 @default.
• W4362656989 hasConcept C141071460 @default.
• W4362656989 hasConcept C14184104 @default.
• W4362656989 hasConcept C168563851 @default.
• W4362656989 hasConcept C197934379 @default.
• W4362656989 hasConcept C2778375690 @default.
• W4362656989 hasConcept C71924100 @default.
• W4362656989 hasConceptScore W4362656989C118487528 @default.
• W4362656989 hasConceptScore W4362656989C126322002 @default.
• W4362656989 hasConceptScore W4362656989C141071460 @default.
• W4362656989 hasConceptScore W4362656989C14184104 @default.
• W4362656989 hasConceptScore W4362656989C168563851 @default.
• W4362656989 hasConceptScore W4362656989C197934379 @default.
• W4362656989 hasConceptScore W4362656989C2778375690 @default.
• W4362656989 hasConceptScore W4362656989C71924100 @default.
• W4362656989 hasIssue "5" @default.
• W4362656989 hasLocation W43626569891 @default.
• W4362656989 hasLocation W43626569892 @default.
• W4362656989 hasLocation W43626569893 @default.
• W4362656989 hasOpenAccess W4362656989 @default.
• W4362656989 hasPrimaryLocation W43626569891 @default.
• W4362656989 hasRelatedWork W2003938723 @default.
• W4362656989 hasRelatedWork W2027450457 @default.
• W4362656989 hasRelatedWork W2047967234 @default.
• W4362656989 hasRelatedWork W2087016115 @default.
• W4362656989 hasRelatedWork W2118496982 @default.
• W4362656989 hasRelatedWork W2349164817 @default.
• W4362656989 hasRelatedWork W2439875401 @default.
• W4362656989 hasRelatedWork W3048696992 @default.
• W4362656989 hasRelatedWork W4238867864 @default.
• W4362656989 hasRelatedWork W2525756941 @default.
• W4362656989 hasVolume "141" @default.
• W4362656989 isParatext "false" @default.
• W4362656989 isRetracted "false" @default.
• W4362656989 workType "article" @default.